Infusions of antigen-specific T cells have yielded therapeutic responses in patients with
pathogens and tumors. To broaden the clinical application of adoptive immunotherapy …

The broad field of gene therapy promises a number of innovative treatments that are likely to
become important in preventing deaths from cancer. In this review, we discuss the history …

Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled
by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and …

Transcription activator-like effector nucleases (TALENs) are programmable nucleases that
join FokI endonuclease with the modular DNA-binding domain of TALEs. Although zinc …

A number of human diseases stem from defective genes. One approach to treating such
diseases is to replace, or override, the defective genes with normal genes, an approach …

Tumor necrosis factor (TNF-α) is capable of inducing apoptosis and is a promising candidate
for genetic engineering drugs in cancer therapy; however, the serious side-effects of TNF-α …

Increasing evidence reveals that random insertion of gene transfer vectors into the genome
of repopulating hematopoietic cells may alter their fate in vivo. Although most insertional …

The widespread clinical implementation of gene therapy requires the ability to stably
integrate genetic information through gene transfer vectors in a safe, effective, and …

The stable introduction of therapeutic transgenes into human cells can be accomplished
using viral and nonviral approaches. Transduction with clinical-grade recombinant viruses …

Over the last few years, hydrodynamic tail vein delivery has established itself as a simple,
yet very effective method for gene transfer into small rodents. Hydrodynamic delivery of …